Company had lowered expectation to $89M
SANTA ROSA — Medical device maker TriVascular Technologies, Inc. (Nasdaq: TRIV) on Tuesday said it netted $101.4 million from its initial public offering of stock.
The Santa Rosa-based company said it sold more than 8 million shares on the Nasdaq exchange at $12 each. That includes an additional 975,000 shares sold pursuant to the underwriter’s option. The company’s shares began trading on April 16.
J.P. Morgan Securities LLC and Credit Suisse Securities (USA) acted as joint book-running managers for the offering. Canaccord Genuity and Stifel, Nicolaus & Company were co-managers.
TriVascular is the third North Bay company to go public this year, all in the life sciences industry. Shares of Novato-based rare-disorder drug developer Ultragenyx Pharmaceutical started trading Jan. 31, and of Santa Rosa-based pharmaceutical developer Ruthigen on March 24.
It’s also the fifth North Bay company to go public in the past 12 months. The others were Petaluma-based telecommunications equipment and software developer Cyan and Healdsburg-based wine producer Truett-Hurst.
TriVascular was initially seeking $100 million on shares priced at $13–$15, but a week ago the company lowered its expectations to about $89.7 million, based on $12 a share. But today, TriVascular said it sold more than 8 million shares, far more than the initial 6.5 million in common stock that it had initially expected.
TriVascular said in its March 10 prospectus that funds from the IPO would go toward expanded marketing of its Ovation Prime Abdominal Stent Graft System, as well as paying off a loan from Boston Scientific.
The company reported a net loss of $50.3 million last year on revenues of $19.5 million. It had a deficit of $238.5 million through last year, and cash and equivalents totaled $38.1 million, according to the prospectus.
In 2005, the company was acquired by Boston Scientific, which later closed TriVascular as a cost-cutting measure. TriVascular returned in 2008 after raising $65 million to re-acquire itself from Boston Scientific.
TriVascular’s Ovation system, which the company describes as the lowest-profile commercially available device for the treatment of abdominal aortic aneurysms, received approval from the U.S. Food and Drug Administration in October 2012 and by the European Commission in August 2010. It has been used to treat more than 3,000 patients across 25 countries in clinical trials, according to the company.
Copyright © 1988–2015 North Bay Business Journal
View the policy for linking to website content.